Hypophagia and body weight loss by tirzepatide are accompanied by fewer GI adverse events compared to semaglutide in preclinical models
Science Advances · 20.06.2025 · 11 (25)
DOI: 10.1126/sciadv.adu1589 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 20.06.2025. Verfasst von Tito Borner und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biobehavioral Health Sciences, University of Pennsylvania, School of Nursing, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Weight Loss, Tirzepatide. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.
Themen: Patientensicherheit
Abstract (Originalsprache)
Glucagon-like peptide-1 receptor (GLP-1R)/glucose-dependent insulinotropic peptide receptor (GIPR) agonistic analogs have yielded superior results in enhancing glycemic control and weight management compared to GLP-1R agonism alone. Intriguingly, GIPR agonism appears to induce antiemetic effects, potentially alleviating part of the nausea and vomiting side effects common to GLP-1R agonists like semaglutide. Here, we show in rats and shrews that GIPR agonism blocks emesis and attenuates other malaise behaviors elicited by GLP-1R activation while maintaining reduced food intake and body weight loss and improved glucose tolerance. The GLP-1R/GIPR agonist tirzepatide induced significantly fewer side effects than equipotent doses of semaglutide. These findings underscore the therapeutic potential of combined pharmaceutical strategies activating both incretin systems, leading to enhanced therapeutic index and reduced occurrence of nausea and vomiting for obesity and diabetes treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biobehavioral Health Sciences, University of Pennsylvania, School of Nursing, Philadelphia, PA, USA.
- Department of Psychiatry, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
- Department of Biological Sciences, University of Southern California, Los Angeles, CA, USA.
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IA, USA.
- Institute of Diabetes, Obesity and Metabolism and School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, USA.
ORCID-Profile: Tito Borner, Allison M Pataro, Alex D White, Serena X Gao, Marcos J Sanchez-Navarro, Allaha Z Mohiby, Francis S Willard, Harvey J Grill, Minrong Ai, Matthew R Hayes, Bart C De Jonghe
Förderung
- NIDDK NIH HHS
Zitieren
APA
Borner, T., Pataro, A. M., Doebley, S. A., Furst, C. D., White, A. D., Gao, S. X., Chow, A., Sanchez-Navarro, M. J., Ghidewon, M. Y., Halas, J. G., Mohiby, A. Z., Willard, F. S., Grill, H. J., Ai, M., Samms, R. J., Hayes, M. R., & De Jonghe, B. C. (2025). Hypophagia and body weight loss by tirzepatide are accompanied by fewer GI adverse events compared to semaglutide in preclinical models. Science Advances, 11(25). https://doi.org/10.1126/sciadv.adu1589
Vancouver
Borner T, Pataro AM, Doebley SA, Furst CD, White AD, Gao SX, et al. Hypophagia and body weight loss by tirzepatide are accompanied by fewer GI adverse events compared to semaglutide in preclinical models. Science Advances. 2025;11(25). doi:10.1126/sciadv.adu1589
BibTeX
@article{Borner2025,
author = {Borner, Tito and Pataro, Allison M and Doebley, Sarah A and Furst, Charles D and White, Alex D and Gao, Serena X and Chow, Angela and Sanchez-Navarro, Marcos J and Ghidewon, Misgana Y and Halas, Julia G and Mohiby, Allaha Z and Willard, Francis S and Grill, Harvey J and Ai, Minrong and Samms, Ricardo J and Hayes, Matthew R and De Jonghe, Bart C},
title = {Hypophagia and body weight loss by tirzepatide are accompanied by fewer GI adverse events compared to semaglutide in preclinical models},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {25},
doi = {10.1126/sciadv.adu1589}
}
EUVIMED